Introduction {#Sec1}
============

The diagnosis of idiopathic normal pressure hydrocephalus (iNPH) in elderly patients is based on the presence of symptoms that include gait disturbance, dementia, and urinary incontinence \[[@CR1], [@CR11], [@CR12], [@CR25], [@CR26]\]. These symptoms are also present in numerous neurodegenerative disorders, including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and Parkinson's disease. iNPH is classically regarded as one of the reversible dementias. However, the results of shunting are often unsatisfactory, with greater improvement encountered in early disease and when memory deficit is only mild or absent \[[@CR27]\].

With careful diagnostic evaluation, positive outcome after shunt surgery may reach as much as 75-87% \[[@CR9], [@CR10], [@CR13], [@CR33], [@CR36], [@CR38]\]. To date, adjunctive tests for confirming the diagnosis of iNPH are not unavailable. Cerebrospinal fluid (CSF)-based diagnosis of AD includes the measurement of β-amyloid 1-42 (Aβ1-42) and total tau (t-tau) protein levels \[[@CR4], [@CR20], [@CR32]\]. For the diagnosis of mild cognitive impairment (MCI), AD and frontotemporal lobe degeneration (FTLD), the CSF biomarkers Aβ42, Aβ40, t-tau and phosphorylated tau (p-tau) have been reported to be most useful \[[@CR7], [@CR19]\]. It has been estimated that the measurement of amyloid β and p-tau levels in the CSF exhibits greater than 85% sensitivity in the diagnosis of AD \[[@CR32]\].

In a recent study using proteome analysis of CSF in iNPH patients, we reported a significant increase in the levels of leucine-rich alpha-2-glycoprotein (LRG) in iNPH patients compared to a control group \[[@CR23]\], suggesting that LRG may be a useful biomarker for iNPH diagnosis.

LRG was isolated from human serum by Haupt and Baundner in 1977 \[[@CR14]\] and its amino acid sequence was determined in 1985. The LRG consists of 312 amino acid residues, 66 of which are leucines. This protein contains eight repeating consensus sequences, each of which consists of 24 amino acid residues and exhibits a periodic pattern in the occurrence of leucine, proline, and asparagines. This consensus sequence, termed the leucine-rich repeat (LRR), has now been found in over 55,000 sequences in the Pfam database of protein alignments \[[@CR24], [@CR37]\]. In the serum, it has been reported that LRG could be a marker of granulocytic differentiation and its expression was up-regulated during neutrophil differentiation \[[@CR31]\].

The human LRG gene localizes to chromosome 19p13.3 and its protein is known to exist in the extracellular space. LRG is co-expressed with transforming growth factor βI type II receptor (TGF βR-II)\[[@CR22]\] and the LRG amino acid sequence contains a putative membrane-binding region, thus suggesting potential binding with TGF βR-II on the cell surface. LRG is thought to bind to collagen and fibronectin, and some authors believe that LRG also binds to TGF-β through collagen \[[@CR22]\].

In the current study, we report the establishment of a novel procedure for simultaneously measuring levels of LRG and total tau protein \[[@CR21]\], a marker of neuronal degeneration in the CSF. We then compare these levels with tap test results and successful shunt outcomes.

Materials and methods {#Sec2}
=====================

Patients and sample collection {#Sec3}
------------------------------

This study was conducted over a period of 36 months between January 2006 and December 2008 on consecutive, unselected admissions to our program for iNPH treatment patients with clinically suspected iNPH \[[@CR28], [@CR35]\]. The iNPH was clinically diagnosed in these patients according to the standard classic triad of gait impairment, urinary incontinence and impaired mental function, supported by ventricular dilatation and dilatation of Sylvian fissures, and narrowing of sulci and subarachnoid spaces over the high convexity without significant cerebral atrophy on CT or MRI. Patients with secondary NPH (e.g., following meningitis, hemorrhage, brain tumor, or trauma) were not included in this study. A tap test involving the removal of 30 ml of CSF with an 18-gauge lumbar puncture needle was performed in 90 patients (53 men, 37 women; mean age 73.4 years; range: 57 to 86 years). Tap test evaluation criteria were consistent with Japanese guidelines for iNPH \[[@CR17], [@CR18]\] within 1 week after removal of CSF, and were deemed positive on any of the following findings: (1) improvement of any item on the "Japanese normal pressure hydrocephalus grading scale revised" (JNPHGS-R)\[[@CR28]\] (Table [1](#Tab1){ref-type="table"}), (2) ≥ 10% improvement on the 3-m up-and-go test or (3) ≥ three-point improvement on the Mini Mental State Examination (MMSE)\[[@CR8]\]. LRG and total tau protein levels were simultaneously measured in tap test CSF samples. Lumbar puncture was performed in the morning under standard condition. A 10-ml CSF sample was collected and gently mixed to avoid gradient effects. All CSF samples with \> 500 erythrocytes/μl were excluded. All CSF samples were centrifuged to remove cells and debris, aliquoted, and stored at --80°C pending biochemical analysis. Total tau was measured by sandwich ELISA (Innotest hTAU-Ag; Innogenetics, Ghent, Belgium). \[[@CR30]\] Nishimura et al. suggest that the appropriate borderline should be 200--400 pg/ml because 91.4% of AD cases had a level of more than 200 pg/ml and 100% of neurological control group subjects had a level of less than 400 pg/ml. The tau protein kit recommends a cut-off value of clinical significance at 200 pg/ml of tau in the CSF, with a sensitivity and specificity for total tau 0.914 and 0.521, respectively. In the present study, the cut-off value was set at 200 pg/ml to rule out neurodegenerative diseases, mainly AD. Table 1Grading scale for normal pressure hydrocephalus (NPH)^a^GradeDefinitionGait disturbance 0Normal 1Unstable, but independent gait 2Walking with one cane 3Walking with two canes or a walker frame 4Walking not possibleDementia 0Within normal range 1No apparent dementia but apathetic 2Socially dependent but independent at home 3Partially dependent at home 4Totally dependentUrinary incontinence 0Absent 1Absent but with pollakisuria or urinary urgency 2Sometimes at night 3Sometimes even during the day 4Frequent^a^Established by the Research Committee on Intractable Hydrocephalus, Ministry of Health and Welfare of Japan, 1996. The grades of gait disturbance, dementia, and urinary incontinence are added to obtain the total grade, ranging from 0 to 12. (Mori et al. From Ref. 23)

The LRG antibody was co-developed with Immuno-Biological Laboratories Co., Ltd. (IBL©) in order to prepare a sandwich ELISA kit (Human LRG Assay Kit-IBL).

Informed consent was obtained from families prior to shunt placement for the 52 patients (33 men, 19 women; mean age 73.5 years; range 57--86 years) who demonstrated a positive tap test. Lumboperitoneal shunts (LPS) or ventriculoperitoneal shunts (VPS) were utilized and adjustable valves were used in all patients (Cylindrical Valve with Prechamber® No.82-3110 for VPS and In-Line Valve with SIPHONGUARD® No.82-3832 for LPS, ©Codman-Hakim, Johnson & Johnson, Raynham, MA).

We evaluated symptom improvements (gait disturbance, urinary incontinence) and higher cerebral functions, MMSE and frontal assessment battery; FAB \[[@CR6]\]. Surgical outcome was evaluated 12 months post-operatively. A shunt responder (SR) was defined as a ≥ 1-grade improvement on the JNPHGS-R. MRI follow-up was done 3 months, 6 months, and 12 months after the shunt. If a patient had not improved clinically and the ventricular system had not decreased in size at the re-examination, the shunt was tested by radionuclide shuntography and was surgically corrected if malfunctioning. In case of subsequent shunt surgery after shunt replacement caused by dysfunction, values obtained 12 months after the latest operation were used as post-operative variables.

The study was approved by the ethics committee of Juntendo University. All patients included in the study, or their relatives, gave informed consent to their participation.

Statistical analysis {#Sec4}
--------------------

All statistical analyses in clinical studies were performed with the Statistical Package of the Social Sciences (SPSS Version 18.0; Cary, NC, USA).

We calculated the relationship between sensitivity and specificity for SR vs. SNR by ROC curve analysis. The "optimum" cut-off value from the ROC curve was the point at which the sum of sensitivity and specificity was maximal. These calculated protein cut-off values were also used to distinguish SR from the SNR, which were the neurodegenerative type of diseases and other dementia conditions.

The*t* test was used to investigate differences in demographics and levels of tau, and LRG in the CSF between the two pathologic groups. The difference between the pre- and post-operative values was calculated for each index, and the mean of the differences was calculated as an overall result after shunt surgery. Patients showing mean of difference \> 0.05 were considered improved, which corresponded to the clinical impression in each case. A*p* value \< 0.01 was considered significant.

Preparation of the human LRG assay Kit-IBL {#Sec5}
------------------------------------------

A sandwich ELISA assay was developed to measure CSF, serum/plasma, and urinary LRG levels. A key feature of this portion of the study was the development of specific antibodies directed against LRG. We produced a human LRG (329) antibody directed against an amino acid sequence in the LRG C-terminus (peptide amino acid sequence: AGPEAVKGQTLLAVAKSQ) and a human LRG (162) antibody directed against an amino acid sequence located within close proximity to the N-terminus (peptide amino acid sequence: GLKALGHLD LSGNRLRKL). Each antigenic site was found to be involved in maleimide-activated peptide synthesis with binding to bovine serum thyroglobulin. The antigen (100 μg) was then mixed with Freund's complete adjuvant and was used to immunize rabbits both subcutaneously and intradermally. For booster immunization, the antigen (100 μg) and Freund's incomplete adjuvant were both injected subcutaneously and intradermally in eight doses at 2-week intervals. The antiserum obtained by immunization was purified on an antigen affinity column prepared by binding the antigen peptide to Activated Thiol Sepharose 4B (GE Healthcare). After adsorption with D-PBS buffer (pH 7.4), antibodies were eluted using 0.2 M glycine buffer (pH 2.5). This procedure provided a highly specific polyclonal antibody.

Measurement of LRG levels using the human LRG assay Kit-IBL {#Sec6}
-----------------------------------------------------------

The sandwich ELISA assay was developed using the human LRG (162) and LRG (329) antibodies. The human LRG (162) antibody was diluted in 0.1 M carbonate buffer (2 μg/100 μl/well), immobilized on ELISA plates and blocked in BSA solution. A human LRG reference standard and the samples (100 μl/well) were added and the trap-precoated plates were covered with plate lids and incubated overnight at 4°C to select for human LRG in solution. The samples were repeatedly washed in PBS containing 0.05% Tween 20 and then incubated with the horseradish peroxidase (HRP)-conjugated Fab fragment of the human LRG (329) antibody (100 μl/well) at 37°C for 30 min. The labeled Fab fragment is known to bind HRP by the maleimide method and was purified by gel filtration. The samples were then washed in PBS containing 0.05% Tween 20 and the HRP color substrate tetra methyl benzidine (TMB, 100 μl/well) was added. The color reaction was then quenched with 1 N sulfuric acid and measured at 450 nm by absorption \[i Mark™ Microplate Reader (Bio-Red©)\].

Assay values were calculated using a calibration curve that had been prepared in advance using a reference product containing a known LRG concentration.

Results {#Sec7}
=======

Total LRG and tau levels in CSF samples obtained from 52 patients who underwent shunt placement were compared between the shunt responder (SR) group, which demonstrated improved symptoms following shunt placement, and the shunt nonresponder (SNR) group, which demonstrated no clinical benefit following shunt placement. LRG levels were found to be significantly higher in the SR group (96.8 ± 44.6 ng/ml \[mean ± SD\]) than in the SNR group (29.2 ± 35.1 ng/ml;*p* \< 0.01) (Fig. [1a](#Fig1){ref-type="fig"}). Tau protein levels in the CSF did not differ significantly between the SR group (167.4 ± 105.4 pg/ml) and the SNR group (264.9 ± 209.5 pg/ml;*p* \> 0.05) (Fig. [1b](#Fig1){ref-type="fig"}). Fig. 1*SR* shunt responder,*SNR* shunt nonresponder. Levels of CSF LRG (A), tau protein (B) ratio in studied groups. Each*blue circle* represents shunt responders and*red triangles* represent the shunt nonresponder individual.*Horizontal lines* indicate median values. **a** Correlation between LRG and SR and SNR. LRG levels were found to be significantly higher in the SR group (96.8 ± 44.6 ng/ml \[mean ± SD\]) than the SNR group (29.2 ± 35.1 ng/ml; \*\**p* \< 0.01). **b** Correlation between tau and SR and SNR. Tau protein levels in the CSF did not significantly differ between the SR group (167.4 ± 105.4 pg/ml) and the SNR group (264.9 ± 209.5 pg/ml;*p* \> 0.05)

Scatter plots were prepared for LRG and tau values in all 90 patients, with LRG on the vertical axis and tau on the horizontal axis (Fig. [2a](#Fig2){ref-type="fig"}). As can be observed, many negative tap test patients demonstrated high tau levels, irrespective of whether low or high LRG levels were recorded. A comparison of the tau protein levels identified in the tap test-positive and -negative groups for all 90 patients showed a significant difference between the positive (186.8 ± 133.3 pg/ml) and negative group (331.5 ± 277.6 pg/ml;*p* \< 0.05). In other words, the determination of CSF tau protein levels could potentially play an adjunctive role in the CSF diagnosis of iNPH using LRG levels. Subsequently, patients were classified into groups based on their LRG and tau protein levels, and their symptom improvement was assessed by the tap test and shunt placement. Fig. 2LRG and total tau protein levels in tap tests 90 cases. **a** Scatter plot of the CSF LRG and total tau protein levels in 90 patients who underwent tap tests. Each*white circle* represents tap test-positive patients and the*yellow square* represents tap test-negative patients. The tau protein kit used in the present study (Innotest hTAU-Ag; Innogenetics) recommends the cut-off value for clinical manifestation at 200 pg/ml of tau in the CSF (the*solid line*). **b** Scatter plot of the CSF LRG and total tau protein levels in 52 patients who underwent shunt replacement. Each*white circle* represents shunt responders, and the*red triangle* represents the shunt nonresponder individual. ROC curve analysis indicated that the optimum cut-offs (*solid line*) for SR vs. SNR was 67 ng/ml for LRG

The sensitivity and specificity for LRG in CSF for differentiation of SR from SNR were determined by ROC curve analysis (Fig. [3](#Fig3){ref-type="fig"}). The optimum cut-off was found at 67 ng/ml. ROC curve analysis with area under the curve (AUC) and SE calculated, 0.792 and 0.078, respectively. The sensitivity and specificity for LRG are 0.816 and 0.786, respectively. Fig. 3ROC curve analysis for LRG in CSF for differentiation of SR from SNR. ROC curve analysis with area under the curve (AUC) and SE calculated using Statistical Package for the Social Sciences (SPSS). The cut-off is given for sensitivity + specificity maximized for SR vs. SNR. The optimum cut-off was 67 ng/ml for LRG(□). AUC and SE are 0.792 and 0.078, respectively

Four groups were classified based on these cut-off values and were termed group A (LRG ≥ 67 ng/ml, tau \< 200 pg/ml), group B (LRG ≥ 67 ng/ml, tau ≥ 200 pg/ml), group C (LRG \< 67 ng/ml, tau \< 200 pg/ml) and group D (LRG \< 67 ng/ml, tau ≥ 200 pg/ml) (Table [2](#Tab2){ref-type="table"}). Table 2Patient groups according to LRG and TAU levelsGroupTAU \< 200 pg/mlTAU ≥ 200 pg/mlLRG ≥ 67 ng/mlABLRG \< 67 ng/mlCD

The positive tap test results for each group were: group A---31 of 34 patients (91.2%); group B---15 of 21 patients (71.4%); group C---15 of 24 patients (62.5%); and group D---6 of 11 patients (54.2%) (Table [3](#Tab3){ref-type="table"}). We also evaluated outcome results in the 52 patients who underwent shunt placement in terms of SR or SNR. In the group A---22 of 22 patients were SR (100%), in group B---ten of 11 patients were SR (90.9%), in group C---six of 13 patients were SR (46.2%) and in group D---two of six patients were SR (33.3%) (Table [3](#Tab3){ref-type="table"}). Table 3Evaluation of tap test and shunt response by groupGroup AGroup BGroup CGroup DLRG ≥ 67 ng/ml, tau \<200 pg/mlLRG ≥ 67 ng/ml, tau ≥ 200 pg/mlLRG \<67 ng/ml, tau \<200 pg/mlLRG \<67 ng/ml, tau ≥ 200 pg/mlTap test-positive (*n* = 90)31/34 (91.2%)15/21 (71.4%)15/24 (62.5%)6/11 (54.2%)Shunt responder (*n* = 52)22/22 (100%)10/11 (90.9%)6/13 (46.2%)2/6 (33%)

MMSE and FAB tests were performed prior to and 12 months following shunt placement to evaluate the improvement in dementia symptoms. In group A, the mean MMSE and FAB scores at baseline and 12 months markedly improved from 22.05 to 25.65 (±0.96) and 11.38 (±0.68) to 13.08 (±0.57), respectively. In group B, the mean MMSE score improved from 17.62 (±2.03) to 21.62 (±1.96) and the FAB improved from 9.25 (±1.15) to 10.5 (±1.59), but did not improve beyond the score limits of dementia. In group C, the mean MMSE score improved from 22.06 (±1.25) to 24.29 (±1.23) and the FAB score improved slightly from 12.0 (±0.72) to 12.87 (±0.72). In group D, there was almost no improvement, MMSE score improved from 17.25 (±4.55) to 17.75(±4.50) and the FAB improved from 11.33 (±1.86) to 12.33 (±1.20) (Table [4](#Tab4){ref-type="table"}). Table 4Cognitive outcomes (52 patients with shunt placement)Group AGroup BGroup CGroup DMMSE pre (±SE )22.05 (±0.96)17.62 (±2.03)22.06 (±1.25)17.25 (±4.55)12 months after (±SE )25.65 (±0.85)21.62 (±1.96)24.29 (±1.23)17.75 (±4.50)Mean of difference (±SE)3.6 (±0.76)4.0 (±1.25)2.23 (±0.55)0.5 (±0.87)CC0.6560.8060.9050.982*p* value\*\*\*\*\*\*FAB pre (±SE )11.38 (±0.68)9.25 (±1.15)12.0 (±0.72)11.33 (±1.86)12 months after (±SE )13.08 (±0.57)10.5 (±1.59)12.87 (±0.72)12.33 (±1.20)post - pre mean (±SE )1.69 (±0.57)1.25 (±0.86)0.87 (±0.41)1.0 (±2.0)CC0.60.8520.8360.573*p* value\**MMSE* mini mental state examination,*FAB* frontal association battery*SE* standard error,*CC* correlation coefficient*P* value;*p* \< 0.05\*,*p* \< 0.01\*\*

Discussion {#Sec8}
==========

In the brain of AD patients, specific structures such as senile plaques and neurofibrillary tangles (NFT) are often seen \[[@CR34]\]. NFT comprise structures called paired helical filaments (PHF), and the main components are abnormal phosphate compounds of human tau, a cytoskeleton-related protein in neurons \[[@CR15], [@CR16]\]. In general, human tau is mostly absent from CSF. However, neuron destruction in neurodegenerative diseases such as AD releases human tau into the CSF \[[@CR29]\]. Human tau levels are thus an indicator of nerve degeneration, and can be used to rule out psychiatric disorders unaccompanied by nerve degeneration, such as dementia and depression. Due to ethical considerations, shunt surgery was not performed on patients with a negative tap test (i.e., patients in whom symptoms did not improve by the tap test, an established diagnostic test). Diagnostic sensitivity and specificity in the present study were thus obtained only from a group of patients with a positive tap test. The assessment criterion for the tap test was a reduction of ≥ 10% in walk time after tapping. However, with this test, walk time can shorten because subjects are instructed to walk in a charge-like manner, and the cue effect \[[@CR2], [@CR3]\] can make patients consciously improve their time, resulting in numerous false-positive cases. As far as the diagnostic value of a positive tap test is concerned, making the definition stricter by using the modified Rankin scale \[[@CR5]\] lowers the sensitivity, but increases the specificity. The diagnostic standards for the tap test in the present study were not very strict.

In our study, levels of LRG ≥ 67 ng/ml and tau \< 200 pg/ml; group A were associated with increased symptom improvement rates following shunt placement. The higher diagnostic rate obtained using our procedure, which requires only small amounts of CSF, suggests that this method may be useful for diagnosis in patients with lumbar spine degeneration or scoliosis, where lumbar puncture is often difficult, and the inconveniences of the tap test or lumbar drainage can be avoided.

In addition, the findings outlined in our study may also prove useful for predicting the optimal time for shunt surgery in iNPH patients. Among the patients that demonstrated high LRG levels (≥ 67 ng/ml) in the CSF, those that also had a negative tap test tended to demonstrate high tau protein levels (tau ≥ 200 pg/ml). In group A (low tau levels; tau \< 200 pg/ml), only three of 34 patients also had a negative tap test. Of the 22 who were positive and received shunt placement, all 22 showed improvement in their symptoms. In group B (high tau levels), six of the 21 patients had a negative tap test. Of those who were positive and had shunt placement, only one patient failed to demonstrate improvement. In other words, even when LRG levels in CSF are high, the SNR rate remains low if tau protein levels are also high.

It is well established that the tau protein is a marker for neuronal cell death \[[@CR29]\]. In group B (LRG ≥ 67 ng/ml, tau ≥ 200 pg/ml), this indicated either a more advanced iNPH with irreversible neurologic symptoms or co-existing neurodegenerative disorders like a AD. Based on our findings, the prognosis for symptom improvement following shunt placement is greater in the early stages of iNPH before severe neuronal loss occurs, making the perspective for improvement of symptoms better in group A, where CSF tau protein levels were less than 200 pg/ml. In group D, (LRG \< 67 ng/ml, tau ≥ 200 pg/ml), six patients achieved a positive tap test, although four patients (66.6%) demonstrated no symptomatic improvement after shunt placement. Thus, in group D, where the tap test false-positive rate was high, progression to neurodegenerative disease is likely and shunt placement should not be considered beneficial.

Conclusions {#Sec9}
===========

In conclusion, LRG levels in the CSF are a potential biomarker for the diagnosis of iNPH. The combination of a tap test, excluding a false-positive tap test, and the measurement of LRG and tau protein levels in the CSF may accurately predict a group of iNPH patients in whom shunt placement is likely to improve gait disturbance and dementia.
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**Comments**

This paper deals with an intriguing and certainly clinically relevant topic: the possibility of predicting shunting outcome in iNPH patients, using a combination of positive TT and CSF levels of LRG and tau proteins. The combination of such biomarkers, based on a robust cut-off, clearly clustered four groups with specific cognitive outcome as measured by MMSE and FAB changes, 12 months after shunting. The statistical analysis is well conducted and the results are sound. More investigational work is clearly needed in this field.
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